New treatment for colorectal cancer using CF10
Improved Treatment of Colorectal Cancer with CF10
This study is testing a new DNA-based drug called CF10 to see if it works better and has fewer side effects than the standard treatment for advanced colorectal cancer, especially for patients who haven't had success with other therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Deep Creek Pharma, LLC NIH-funded |
| Lab location | 1 site (Yadkinville, United States) |
| Project ID | NIH-10835053 on NIH RePORTER |
What this research studies
This research focuses on developing CF10, a novel DNA-based drug that aims to improve treatment outcomes for patients with colorectal cancer, particularly those with advanced or metastatic disease. The approach involves comparing CF10's effectiveness and safety against the standard treatment, 5-FU, in pre-clinical models. The goal is to demonstrate that CF10 can provide better survival rates and fewer side effects, making it a promising option for patients who have not responded to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with locally advanced or metastatic colorectal cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage colorectal cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment option for colorectal cancer patients.
How similar studies have performed: Previous research has shown promising results with similar DNA-based therapies, indicating potential for success in this novel approach.
Where this research is happening
Yadkinville, United States
- Deep Creek Pharma, LLC — Yadkinville, United States (Active)
Researchers
- Principal investigator: Gmeiner, William H. — Deep Creek Pharma, LLC
- Study coordinator: Gmeiner, William H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.